Application of balsam pear polypeptide in relieving gastrointestinal tract side effects caused by chemotherapeutic drugs

Abstract

The invention discloses application of momordica charantia polypeptide in relieving gastrointestinal tract side effects caused by chemotherapeutic drugs, and relates to the technical field of medicines, the chemotherapeutic drugs are one or more of fluorouracil drugs, platinum drugs, taxane drugs and topoisomerase inhibitors; according to the application of the momordica charantia polypeptide in the aspect of relieving the gastrointestinal tract side effects caused by the chemotherapy drugs, by combining metagenomics and metabonomics analysis, the specific mechanism of the momordica charantia polypeptide in gastrointestinal tract microecological protection after gastric cancer chemotherapy is comprehensively revealed, and the momordica charantia polypeptide can effectively relieve gastrointestinal tract discomfort symptoms occurring after chemotherapy of gastric cancer patients and has the effect of relieving the gastrointestinal tract side effects caused by the chemotherapy drugs. The life quality of a patient is remarkably improved, and the tolerance and confidence of the patient to treatment are enhanced; meanwhile, the balsam pear polypeptide is expected to enhance the intestinal immune function of the patient, improve the overall immunity and help the patient to better resist diseases; in addition, the application serves as a novel auxiliary treatment means, the defect of a single treatment mode of traditional chemotherapy is overcome, and the comprehensive treatment effect is improved.

Description

Technical Field

[0001] The invention relates to medical technology, and in particular to application of bitter melon polypeptide in alleviating gastrointestinal side effects caused by chemotherapy drugs. Background Art

[0002] Gastric cancer is the most common digestive tract malignancy in my country, with tens of thousands of new cases each year. Its high incidence seriously threatens the lives and health of Chinese people. In clinical practice, most gastric cancer patients are already in the middle and late stages when diagnosed, with extensive infiltration of tumor cells, and lose the chance of radical surgery. At this time, chemotherapy becomes one of the main treatment methods, killing tumor cells and inhibiting tumor growth by using cytotoxic drugs. However, while chemotherapy drugs play an anti-cancer role, they can damage normal gastrointestinal cells and cause a series of gastrointestinal side effects. After entering the human body, chemotherapy drugs interfere with the normal metabolism and proliferation of gastrointestinal cells, causing damage to the gastrointestinal mucosa. These side effects not only cause physical and mental pain to patients, but also seriously affect their quality of life, causing patients to fear and resist treatment, reducing treatment compliance, and even causing some patients to give up treatment, or interrupt treatment due to excessive side effects, thereby affecting the treatment effect and prognosis. Therefore, how to effectively alleviate the gastrointestinal side effects of gastric cancer patients after chemotherapy and improve the quality of life and treatment compliance of patients has become an important issue to be solved in the current field of gastric cancer treatment. Summary of the invention

[0003] The purpose of the present invention is to provide an application of Momordica charantia polypeptide in alleviating gastrointestinal side effects caused by chemotherapeutic drugs, so as to solve the above-mentioned deficiencies in the prior art.

[0004] In order to achieve the above object, the present invention provides the following technical solution: application of Momordica charantia polypeptide in alleviating gastrointestinal side effects caused by chemotherapy drugs, wherein the chemotherapy drugs are one or more of fluorouracil drugs, platinum drugs, taxane drugs, and topoisomerase inhibitors.

[0005] Furthermore, the fluorouracil drug is capecitabine or S-1.

[0006] Furthermore, the platinum drug is cisplatin or oxaliplatin.

[0007] Furthermore, the taxane drug is paclitaxel or docetaxel.

[0008] Furthermore, the topoisomerase inhibitor is irinotecan.

[0009] Furthermore, the side effects include affecting the composition of intestinal microbial communities, inducing intestinal inflammatory responses and causing decreased intestinal immune function.

[0010] Compared with the prior art, the application of Momordica polypeptide provided by the present invention in alleviating gastrointestinal side effects caused by chemotherapy drugs comprehensively reveals the specific mechanism of Momordica polypeptide in protecting the gastrointestinal microecology after gastric cancer chemotherapy through the combination of metagenomics and metabolomics analysis. Momordica polypeptide can effectively relieve the gastrointestinal discomfort symptoms that occur after chemotherapy in gastric cancer patients, significantly improve the quality of life of patients, enhance the tolerance and confidence of patients towards treatment; at the same time, Momordica polypeptide is expected to enhance the intestinal immune function of patients, improve the overall immunity, and help patients better resist diseases; in addition, this application, as a new adjuvant treatment method, enriches the treatment options, improves the deficiencies of the traditional single chemotherapy treatment mode, and improves the comprehensive treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the following will briefly introduce the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments recorded in the present invention, and those of ordinary skill in the art can also obtain other drawings based on these drawings.

[0012] Figure 1 Schematic diagram of the β-diversity results of the intestinal flora provided by the embodiment of the present invention;

[0013] Figure 2 Schematic diagram of the α-diversity results of the intestinal flora provided by the embodiment of the present invention;

[0014] Figure 3 Histogram of the relative abundance of phyla of the intestinal flora provided by the embodiment of the present invention;

[0015] Figure 4 Schematic diagram of the composition of different microbial communities in the intestine provided by the embodiment of the present invention;

[0016] Figure 5 Schematic diagram of the relative abundance of metabolites provided by the embodiment of the present invention. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0017] In order to enable those skilled in the art to better understand the technical solutions of the present invention, the following will further introduce the present invention in detail with reference to the drawings.

[0018] Example 1:

[0019] Application of Momordica charantia polypeptide in alleviating gastrointestinal side effects caused by chemotherapeutic drugs, where the chemotherapeutic drug is one or more of fluorouracil drugs, platinum drugs, taxane drugs, and topoisomerase inhibitor drugs; the fluorouracil drugs are capecitabine or tegafur; the platinum drugs are cisplatin or oxaliplatin; the taxane drugs are paclitaxel or docetaxel; the topoisomerase inhibitor drugs are irinotecan; the side effects are affecting the composition of the intestinal microbial community, triggering intestinal inflammatory reactions, and causing a decline in intestinal immune function.

[0020] Fluorouracil drugs: Drugs such as capecitabine and tegafur. During chemotherapy, these drugs may cause changes in the diversity and richness of the intestinal flora, a decrease in the number of certain beneficial bacteria, and a relative increase in some drug-resistant or harmful bacteria. The damage of these drugs to intestinal epithelial cells leads to impaired intestinal barrier function, making it easier for bacteria and toxins in the intestine to cross the intestinal mucosa, triggering inflammatory reactions, and having a certain impact on the intestinal immune barrier, resulting in a decline in intestinal immune function. In addition, the change in the composition of the intestinal microbial community may also affect the development and function of the intestinal immune system, and thus affect the overall immune function.

[0021] Platinum drugs: Platinum drugs such as cisplatin and oxaliplatin can cause changes in the composition of the intestinal flora, affect the stability of the intestinal internal environment, and thus affect the normal function of the intestine. The stimulation and damage of platinum drugs to the intestinal mucosa may lead to an increase in inflammatory cell infiltration and elevated levels of inflammatory factors in the intestinal mucosa, further exacerbating the intestinal inflammatory state, and affecting intestinal immune function by influencing the activity and number of intestinal immune cells. In addition, the damage to the intestinal mucosa may also weaken the intestinal immune barrier function, making the intestine more vulnerable to pathogen invasion.

[0022] Taxane drugs: Taxane drugs such as paclitaxel and docetaxel can have a certain stimulating effect on the intestinal mucosa, causing intestinal inflammatory reactions. In addition, their regulatory effect on the immune system may also indirectly affect the intestinal inflammatory state; on the one hand, the killing effect of taxane drugs on tumor cells may indirectly affect intestinal immune function; on the other hand, their direct effects on the intestinal microbial community and intestinal mucosa may also have an impact on intestinal immune function.

[0023] Topoisomerase inhibitor drugs: SN-38 produced after the metabolism of irinotecan in the body may be reactivated by bacteria in the intestine, causing toxicity to intestinal cells, and may also affect the normal metabolism and community composition of intestinal microorganisms. The toxic effect of irinotecan on intestinal cells and its impact on intestinal microbial metabolism affect intestinal immune function by influencing the metabolism and composition of intestinal microorganisms. In addition, its toxic effect on the intestinal mucosa may also weaken the intestinal immune barrier, resulting in a decline in intestinal immune function.

[0024] Momordica polypeptide is a natural bioactive substance extracted from Momordica charantia, which has various health care effects. It can promote metabolism, increase energy consumption and fat metabolism; enhance immunity and stimulate macrophage activity; have antioxidant and anti-inflammatory effects, reduce oxidative stress; assist in weight loss; improve blood lipids and lower blood lipid levels; protect pancreatic islet β cells; and has natural ingredients with high safety.

[0025] Example 2:

[0026] Please refer to Figures 1 - 5 , this example provides a technical solution on the basis of Example 1: The effect of Momordica polypeptide on the intestinal microbial community and metabolite composition of gastric cancer patients after chemotherapy.

[0027] By performing sequencing analysis of intestinal microorganisms on patient samples, evaluate the effects of Momordica polypeptide on the diversity, relative abundance and structure of the microbial community.

[0028] Patients diagnosed with gastric cancer in Inner Mongolia region and who have received 2 - 6 cycles of chemotherapy were taken as the research objects, with a total of 100 cases. They have clear clinical diagnoses and no serious complications or other diseases that affect the experimental results. There are 50 patients in each of the experimental group and the control group. The sample size calculation will be based on statistical methods to ensure the reliability and validity of the research results. All participants will sign an informed consent form before enrollment to ensure they fully understand the research purpose and possible risks.

[0029] The patients were divided into an experimental group (Momordica polypeptide) and a control group (only receiving chemotherapy) using the random number table method. Patients in each group will receive treatment in the same hospital to ensure the consistency of treatment conditions.

[0030] Patients in the experimental group will, on the basis of chemotherapy, be supplemented with an appropriate amount of Momordica polypeptide (the dosage and usage are determined according to the results of previous pre-experiments), and the duration is 12 weeks; the control group only receives standard chemotherapy for the same duration; collect fecal samples of the patients for metagenomics and metabolomics analysis.

[0031] 1. Metagenomic analysis:

[0032] Extract microbial DNA from the collected fecal samples, use the PowerSoil DNA Isolation Kit to ensure obtaining high-purity DNA to improve the quality of subsequent experiments; perform 16S rRNA gene sequencing using Illumina MiSeq or Ion Torrent technology, targeting the V3 - V4 region to analyze the diversity and community structure of intestinal microorganisms. Use bioinformatics software such as QIIME2 or Mothur for data processing and analysis, including sequence denoising, clustering, classification and diversity analysis.

[0033] Please refer toFigure 2 In the diversity analysis, there were differences between the experimental group and the control group in the α-diversity index (Shannon index). The α-diversity index of the experimental group was relatively stable, while that of the control group decreased, indicating that momordica polypeptide might contribute to maintaining the diversity of intestinal microbiota.

[0034] Please refer to Figure 1 In the β-diversity analysis, through methods such as principal coordinate analysis (PCoA), significant differences were found in the intestinal microbiota community structures between the experimental group and the control group. The samples of the experimental group clustered together on the PCoA plot, indicating that momordica polypeptide had a unified regulatory effect on the intestinal microbiota community structure.

[0035] Please refer to Figures 3 - 4 For the microbial community composition analysis, at the phylum level, by comparing the relative abundance differences between the experimental group and the control group, it was found that the relative abundances of some beneficial bacteria (such as Bifidobacterium, Lactobacillus, etc.) in the experimental group increased, while the relative abundances of some potentially harmful bacteria (such as Escherichia coli, Enterococcus, etc.) decreased.

[0036] 2. Metabolomics analysis:

[0037] Metabolites were extracted from fecal samples to ensure the integrity and stability of metabolites. UPLC-QTOF / MS or GC-MS technology was used for metabolite analysis to ensure the detection of a wide range of metabolites; software such as XCMS was used for the processing and analysis of raw data to eliminate noise and background interference and complete feature extraction.

[0038] Metabolites were identified by comparing with standards or database matching and were quantitatively analyzed to evaluate their changes between different groups. Online tools such as MetaboAnalyst were used for metabolic pathway analysis to explore the association between metabolite changes and clinical symptoms.

[0039] Please refer to Figure 5 Regarding the types and contents of metabolites, through UPLC-QTOF / MS or GC-MS technology, significant differences in the types and contents of metabolites were detected between the experimental group and the control group. More short-chain fatty acids (such as acetic acid, propionic acid, butyric acid, etc.) might be detected in the experimental group, and these metabolites were closely related to intestinal health.

[0040] For the metabolic pathway analysis, through tools such as MetaboAnalyst for metabolic pathway analysis, it was found that the activities of some metabolic pathways (such as glycolysis, tricarboxylic acid cycle, etc.) in the experimental group were enhanced, while the activities of some metabolic pathways related to inflammatory response or oxidative stress were weakened. This indicates that momordica polypeptide might improve intestinal health by regulating the metabolic functions of intestinal microbiota.

[0041] By methods such as Spearman correlation analysis, a significant correlation was found between the relative abundances of gut microbiota and metabolite contents. The relative abundance of Bifidobacterium was positively correlated with the content of short-chain fatty acids, while the relative abundance of Escherichia coli was positively correlated with the content of certain inflammation-related metabolites.

[0042] Integrating the results of metagenomics and metabolomics analyses, it can be concluded that Momordica charantia polypeptide has a positive impact on the gut microbiota community and metabolic function of gastric cancer patients undergoing chemotherapy. This may help improve the gut health of patients, reduce the side effects brought by chemotherapy, and enhance the quality of life of patients.

[0043] Example 3:

[0044] This example provides a technical solution based on Example 1: the regulatory effect of Momordica charantia polypeptide on the intestinal inflammatory response in gastric cancer patients undergoing chemotherapy: by detecting the changes in relevant inflammatory indicators such as white blood cell count, C-reactive protein, and intestinal mucosal inflammation markers, the impact of Momordica charantia polypeptide on the intestinal inflammatory state of patients was evaluated.

[0045] Blood samples of the patients in Example 2 were collected for detecting the changes in white blood cells, C-reactive protein, and intestinal mucosal inflammation markers.

[0046] White blood cell count: The white blood cell count in the blood sample was detected using an automatic hematology analyzer, strictly following the operating procedures of the instrument. Each sample was detected twice, and the average value was taken.

[0047] C-reactive protein detection: The content of C-reactive protein in the blood sample was determined using immunoturbidimetry, operating according to the kit instructions. A standard curve and quality control products were set for each batch of detections to ensure the accuracy of the detection results.

[0048] Intestinal mucosal inflammation marker detection: Fecal calprotectin and fecal lactoferrin were selected as intestinal mucosal inflammation markers and detected using enzyme-linked immunosorbent assay (ELISA). The operation was strictly carried out according to the kit instructions, and duplicate wells were set for each sample to ensure the reliability of the results. The specific experimental results are as follows in the table:

[0049] Index (unit) Experimental group Control group P value <![CDATA[White blood cell count (×10 9 / L)]]> 6.2±0.8 7.5±1.0 <0.05 C-reactive protein (mg / L) 6.8±1.2 9.5±1.8 <0.05 Fecal Calprotectin (μg / g) 42.3±8.5 65.8±12.3 <0.05 Fecal Lactoferrin (μg / g) 18.6±4.2 32.5±6.8 <0.05

[0050] Please refer to the above table. White blood cell count: Before the start of the experiment, there was no significant difference in the white blood cell count between the experimental group and the control group (P>0.05), indicating that the two groups of patients were comparable in terms of baseline white blood cell levels. After the experiment was completed, the white blood cell count in the experimental group was (6.2±0.8)×10 9 / L, and that in the control group was (7.5±1.0)×10 9 / L. There was a statistically significant difference between the two groups (P < 0.05), indicating that Momordica polypeptide may help reduce the increase in white blood cells caused by chemotherapy and relieve the systemic inflammatory state caused by intestinal inflammatory response.

[0051] Please refer to the above table. C-reactive protein: Before the start of the experiment, there was no significant difference in the C-reactive protein levels between the two groups of patients (P > 0.05). After treatment, the C-reactive protein content in the experimental group was (6.8 ± 1.2) mg / L, and that in the control group was (9.5 ± 1.8) mg / L. The experimental group was significantly lower than the control group (P < 0.05), indicating that Momordica polypeptide can effectively reduce the C-reactive protein level in patients with gastric cancer chemotherapy and relieve the inflammatory response.

[0052] Please refer to the above table. Before the start of the experiment, there were no significant differences in the levels of fecal calprotectin and fecal lactoferrin between the two groups of patients (P > 0.05), and they were comparable. After treatment, fecal calprotectin in the experimental group was (42.3 ± 8.5) μg / g, and fecal lactoferrin was (18.6 ± 4.2) μg / g; fecal calprotectin in the control group was (65.8 ± 12.3) μg / g, and fecal lactoferrin was (32.5 ± 6.8) μg / g. The levels of intestinal mucosal inflammation markers in the experimental group were significantly lower than those in the control group (P < 0.05), indicating that Momordica polypeptide has an obvious regulatory effect on intestinal mucosal inflammation caused by chemotherapy and can reduce the damage and inflammatory response of intestinal mucosa.

[0053] In summary, through rigorous design and detection in this experiment, it was found that Momordica polypeptide has a significant regulatory effect on intestinal inflammatory response in patients with gastric cancer chemotherapy, providing a scientific basis for the clinical application of Momordica polypeptide in assisting the treatment of patients with gastric cancer chemotherapy.

[0054] Example 4:

[0055] On the basis of Example 1, this example provides a technical solution: the regulatory effect of Momordica polypeptide on intestinal immune function in patients with gastric cancer after chemotherapy.

[0056] By detecting the changes in immune-related indicators such as immunoglobulins, inflammatory factors, and intestinal immune cells, evaluate whether Momordica polypeptide can regulate the intestinal immune function of patients.

[0057] Collect blood samples and fecal samples from two groups of patients before treatment (baseline) and 12 weeks after treatment for detecting immune-related indicators and intestinal microbiota-related detection. The sample collection process is standardized to ensure the sample quality.

[0058] The levels of immunoglobulins IgA, IgG, and IgM in blood samples were detected by enzyme-linked immunosorbent assay (ELISA). The operation was carried out strictly according to the kit instructions, and duplicate wells were set for each sample to ensure the reliability of the results.

[0059] The levels of inflammatory factors IL-6, TNF-α, and IL-10 in blood samples were determined by enzyme-linked immunosorbent assay (ELISA). According to the kit instructions, a standard curve and quality control products were set for each batch of detections to ensure the accuracy of the detection results.

[0060] Intestinal immune cells in blood samples, including the proportions and numbers of T cell subsets (CD4+, CD8+), B cells, and NK cells, were detected by flow cytometry. The operation was carried out strictly according to the operating procedures of flow cytometry to ensure the accuracy of the detection results.

[0061] The immune-related index data of all patients were recorded to establish a database, and statistical software was used for analysis. The changes in immune indexes before and after treatment in the experimental group and the control group were compared to judge the regulatory effect of Momordica polypeptide on intestinal immune function. The analysis process strictly followed the statistical principles to ensure the credibility of the results.

[0062] Before treatment, there were no significant differences in the levels of IgA, IgG, and IgM between the experimental group and the control group (P>0.05), indicating that the two groups of patients were comparable in terms of baseline immunoglobulin levels. After treatment, the IgA level in the experimental group was (180.5±32.4) mg / dL, the IgG level was (1020.3±185.6) mg / dL, and the IgM level was (95.6±18.3) mg / dL; the IgA level in the control group was (150.2±28.7) mg / dL, the IgG level was (850.4±160.2) mg / dL, and the IgM level was (80.5±15.2) mg / dL. The immunoglobulin levels in the experimental group were significantly higher than those in the control group (P<0.05), indicating that Momordica polypeptide can increase the immunoglobulin levels in gastric cancer chemotherapy patients and enhance the humoral immune function.

[0063] Before treatment, there were no significant differences in the levels of IL-6, TNF-α, and IL-10 between the two groups of patients (P>0.05). After treatment, the IL-6 level in the experimental group was (12.3±2.8) pg / mL, the TNF-α level was (32.5±6.4) pg / mL, and the IL-10 level was (18.6±3.2) pg / mL; the IL-6 level in the control group was (25.4±5.6) pg / mL, the TNF-α level was (50.2±8.7) pg / mL, and the IL-10 level was (12.3±2.1) pg / mL. The levels of IL-6 and TNF-α in the experimental group were significantly lower than those in the control group (P<0.05), while the IL-10 level was significantly higher than that in the control group (P<0.05), indicating that momordica polypeptide can reduce the levels of pro-inflammatory factors, increase the levels of anti-inflammatory factors, regulate the inflammatory response, and improve the intestinal immune microenvironment.

[0064] Before treatment, there were no significant differences in the proportion and number of intestinal immune cells between the two groups of patients (P>0.05), and they were comparable. After treatment, the proportion of CD4+ cells in the experimental group was (38.5±5.6)%, the proportion of CD8+ cells was (24.3±3.8)%, the proportion of B cells was (12.5±2.3)%, and the proportion of NK cells was (15.6±2.8)%; the proportion of CD4+ cells in the control group was (32.4±4.7)%, the proportion of CD8+ cells was (28.5±4.2)%, the proportion of B cells was (9.8±1.8)%, and the proportion of NK cells was (12.3±2.1)%. The proportion of CD4+ cells in the experimental group was significantly higher than that in the control group (P<0.05), the proportion of CD8+ cells was significantly lower than that in the control group (P<0.05), and the proportions of B cells and NK cells were also higher than those in the control group (P<0.05), indicating that momordica polypeptide can regulate the distribution and number of intestinal immune cells, enhance cellular immune function, and improve the body's immune surveillance and defense capabilities.

[0065] In summary, through rigorous design and multi-dimensional detection in this experiment, it was found that momordica polypeptide has a significant regulatory effect on the intestinal immune function of gastric cancer chemotherapy patients, providing a scientific basis for the clinical application of momordica polypeptide in assisting the treatment of gastric cancer chemotherapy patients, helping to improve the intestinal immune function of patients, and enhancing the quality of life and treatment effect.

[0066] Example Five:

[0067] On the basis of Example One, this example provides a technical solution: the improvement effect of momordica polypeptide on the related symptoms of gastric cancer chemotherapy patients.

[0068] By evaluating the gastrointestinal symptoms, quality of life, pain level, etc. of the patients, analyze the effects of Momordica polypeptide on the physiological and psychological conditions of the patients. Collect relevant data of the two groups of patients before treatment and 12 weeks after treatment, including gastrointestinal symptoms, quality of life, pain level, etc., to ensure that the evaluation process is standardized and the data is accurate and reliable.

[0069] Assessment of gastrointestinal symptoms: Use the Gastrointestinal Symptom Rating Scale (such as the MD Anderson Symptom Inventory, MASI) to evaluate the severity and frequency of symptoms such as nausea, vomiting, diarrhea, constipation, loss of appetite, etc. of the patients. This scale contains multiple dimensions and can comprehensively reflect the gastrointestinal symptom status of the patients. Conduct a questionnaire survey on the patients by trained professional medical staff to ensure the objectivity and accuracy of the evaluation results.

[0070] Assessment of quality of life: Use the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) to evaluate the quality of life of the patients. This questionnaire contains multiple dimensions, such as physical function, role function, emotional function, cognitive function, social function, general health status, and cancer-related symptoms, etc., and can comprehensively reflect the quality of life status of the patients. Let the patients fill in the questionnaire by themselves. For patients with low educational level or difficulty in filling, assist them to complete it by medical staff to ensure the integrity and accuracy of the questionnaire filling.

[0071] Assessment of pain level: Use the Visual Analogue Scale (VAS) to evaluate the pain level of the patients. VAS is a 10-cm long straight line, with one end representing "no pain" and the other end representing "severe pain". The patient marks the corresponding position on the straight line according to their pain perception, and the medical staff measures the distance between the marked point and the "no pain" end and records the pain score in centimeters. At the same time, record the situation of the patients using analgesic drugs, including drug types, doses, and usage frequencies, etc., and comprehensively evaluate the pain level and its impact on the patients' lives.

[0072] Record the evaluation data of all patients, establish a database, and use statistical software for analysis. Compare the changes in relevant symptoms before and after treatment between the experimental group and the control group, judge the improvement effect of Momordica polypeptide on the physiological and psychological conditions of the patients. The analysis process strictly follows statistical principles to ensure the credibility of the results.

[0073] Improvement of gastrointestinal symptoms: Before treatment, there was no significant difference in the gastrointestinal symptom scores between the experimental group and the control group (P>0.05), indicating that the two groups of patients were comparable in terms of baseline gastrointestinal symptoms. After treatment, the total gastrointestinal symptom score of the experimental group was (18.5±4.2) points, and that of the control group was (28.7±5.6) points. The experimental group was significantly lower than the control group (P<0.05), indicating that momordica polypeptide can effectively relieve the gastrointestinal symptoms of gastric cancer patients undergoing chemotherapy and improve the comfort of patients. In terms of specific symptoms, the incidence of nausea and vomiting in the experimental group was significantly lower than that in the control group (P<0.05), and the frequency and severity of diarrhea and constipation were also significantly reduced (P<0.05). The symptom of loss of appetite was significantly improved (P<0.05), and the overall gastrointestinal function of the patients recovered well.

[0074] Improvement of quality of life: Before treatment, there was no significant difference in the scores of each dimension of the quality of life between the two groups of patients (P>0.05), and they were comparable. After treatment, the scores of the experimental group in dimensions such as physical function, role function, emotional function, cognitive function, and social function were all significantly higher than those of the control group (P<0.05), and the overall health status and life satisfaction were also significantly improved (P<0.05). For example, the physical function score of the experimental group was (65.4±12.3) points, and that of the control group was (52.8±10.7) points; the role function score was (60.2±11.6) points, and that of the control group was (45.3±9.8) points; the emotional function score was (68.7±13.2) points, and that of the control group was (54.6±11.3) points. This indicates that momordica polypeptide can significantly improve the quality of life of gastric cancer patients undergoing chemotherapy and enhance their social adaptability and psychological well-being.

[0075] Reduction of pain intensity: Before treatment, there was no significant difference in the VAS pain scores between the two groups of patients (P>0.05), and they were comparable. After treatment, the VAS pain score of the experimental group was (3.2±1.1) points, and that of the control group was (5.6±1.5) points. The experimental group was significantly lower than the control group (P<0.05), indicating that momordica polypeptide can effectively reduce the pain intensity of gastric cancer patients undergoing chemotherapy and improve the pain tolerance of patients. At the same time, the proportion of patients in the experimental group using strong analgesics was significantly lower than that in the control group (P<0.05), indicating that momordica polypeptide may reduce the occurrence and intensity of pain by regulating the immune function and inflammatory response of the body, reduce the dependence of patients on analgesics, and further improve the quality of life of patients.

[0076] In summary, through rigorous design and multi-dimensional evaluation in this experiment, it was found that momordica polypeptide has a significant improvement effect on the gastrointestinal symptoms, quality of life, and pain intensity of gastric cancer patients undergoing chemotherapy, providing comprehensive scientific basis for the clinical application of momordica polypeptide in assisting the treatment of gastric cancer patients undergoing chemotherapy, and helping to improve the treatment compliance and rehabilitation effect of patients.

[0077] Only certain exemplary embodiments of the present invention have been described above by way of illustration. Without doubt, for those of ordinary skill in the art, the described embodiments can be modified in various different ways without departing from the spirit and scope of the present invention. Therefore, the above drawings and description are illustrative in nature and should not be construed as limiting the scope of protection of the claims of the present invention.

Claims

1. Use of Momordica charantia polypeptide in relieving gastrointestinal side effects caused by chemotherapy drugs, characterized in that, The chemotherapy drug is one or more of fluorouracil drugs, platinum drugs, taxane drugs, and topoisomerase inhibitor drugs.

2. Use of the balsam pear polypeptide according to claim 1 in alleviating gastrointestinal side effects caused by chemotherapy drugs, characterized in that, The fluorouracil drugs are capecitabine or tegafur-uracil.

3. Use of the balsam pear polypeptide according to claim 1 in alleviating gastrointestinal side effects caused by chemotherapeutic drugs, characterized in that, The platinum drugs are cisplatin or oxaliplatin.

4. Use of Momordica charantia polypeptide according to claim 1 in relieving gastrointestinal side effects caused by chemotherapeutic drugs, characterized in that, The taxane drugs are paclitaxel or docetaxel.

5. Use of Momordica charantia polypeptide according to claim 1 in alleviating gastrointestinal side effects caused by chemotherapeutic drugs, characterized in that, The topoisomerase inhibitor drugs are irinotecan.

6. Use of the balsam pear polypeptide according to claim 1 in alleviating gastrointestinal side effects caused by chemotherapy drugs, characterized in that, The side effects are affecting the composition of the intestinal microbiota, triggering intestinal inflammatory responses, and causing a decline in intestinal immune function.

Images